

Bluebird bio forms potential \$4.2M deal with French Muscular Dystrophy Association

Mass High Tech: The Journal of New England Technology

Bluebird bio, a Cambridge genetics-focused biotech firm, has entered into a deal, worth up to \$4.2 million, with the French Muscular Dystrophy Association (AFM). The agreement focuses on the development of LentiGlobin, a treatment intended for beta-thalassemia and sickle cell anemia.

The company will take in about \$1.4 million in an upfront cash payment to support LentiGlobin's development. Another \$2.8 million in credit may be used by bluebird bio to manufacture cGMP clinical trial material at AFM-developed nonprofit research center Généthon, where bluebird has an existing [gene therapy manufacturing agreement](#) [1].

[SOURCE](#) [2]

Source URL (retrieved on 01/30/2015 - 5:04am):

<http://www.mdtmag.com/news/2011/03/bluebird-bio-forms-potential-42m-deal-french-muscular-dystrophy-association>

Links:

[1] <http://www.masshightech.com/stories/2010/12/13/daily27-Bluebird-bio-French-firm-team-in-gene-therapy-manufacturing.html>

[2] <http://www.masshightech.com/stories/2011/03/14/daily37-Bluebird-bio-forms-potential-42M-deal-with-French-Muscular-Dystrophy-Association.html>